Compassionate Use of Pennsaid Topical Lotion (Diclofenac) in Osteo or Rheumatoid Arthritis
Launched by MALLINCKRODT · Apr 16, 2012
Trial Information
Current as of April 24, 2025
Approved for marketing
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • diagnosed osteo or rheumatoid arthritis
- • Oral NSAIDs were not deemed appropriate treatment
- • Completed diclofenac sensitivity patch test with negative result
- • Signed informed consent form
- Exclusion Criteria:
- • At the discretion of the physician and HPB
About Mallinckrodt
Mallinckrodt is a global leader in specialty pharmaceuticals and medical imaging, dedicated to developing and delivering innovative treatments for patients with serious and chronic conditions. With a strong focus on areas such as pain management, neurology, and rare diseases, Mallinckrodt combines advanced science with a commitment to patient care. The company is actively engaged in clinical trials to evaluate the safety and efficacy of its products, striving to address unmet medical needs and improve patient outcomes. Through its rigorous research and development efforts, Mallinckrodt aims to enhance the quality of life for patients around the world while maintaining high standards of ethical conduct and regulatory compliance.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials
Related Blog Entries
View all
